Protagonist Therapeutics (PTGX) Competitors $59.60 +1.49 (+2.56%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$59.58 -0.02 (-0.03%) As of 09/4/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX vs. VTRS, RDY, ASND, QGEN, MRNA, BBIO, ELAN, VRNA, ROIV, and GRFSShould you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Protagonist Therapeutics vs. Its Competitors Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S QIAGEN Moderna BridgeBio Pharma Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Grifols Viatris (NASDAQ:VTRS) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Do institutionals & insiders believe in VTRS or PTGX? 79.9% of Viatris shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 0.1% of Viatris shares are owned by insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer VTRS or PTGX? In the previous week, Protagonist Therapeutics had 14 more articles in the media than Viatris. MarketBeat recorded 17 mentions for Protagonist Therapeutics and 3 mentions for Viatris. Protagonist Therapeutics' average media sentiment score of 1.49 beat Viatris' score of -0.01 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Protagonist Therapeutics 15 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is VTRS or PTGX more profitable? Protagonist Therapeutics has a net margin of 24.88% compared to Viatris' net margin of -24.57%. Viatris' return on equity of 16.54% beat Protagonist Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viatris-24.57% 16.54% 7.06% Protagonist Therapeutics 24.88%8.12%7.41% Which has higher earnings & valuation, VTRS or PTGX? Protagonist Therapeutics has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViatris$14.74B0.82-$634.20M-$2.90-3.56Protagonist Therapeutics$434.43M8.53$275.19M$0.7085.14 Do analysts recommend VTRS or PTGX? Viatris currently has a consensus price target of $10.40, indicating a potential upside of 0.68%. Protagonist Therapeutics has a consensus price target of $67.20, indicating a potential upside of 12.75%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protagonist Therapeutics is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk and volatility, VTRS or PTGX? Viatris has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. SummaryProtagonist Therapeutics beats Viatris on 15 of the 17 factors compared between the two stocks. Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTGX vs. The Competition Export to ExcelMetricProtagonist TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.62B$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio85.1420.8975.9926.43Price / Sales8.53458.96546.94119.09Price / Cash12.8644.5237.0558.92Price / Book5.269.9310.916.06Net Income$275.19M-$53.38M$3.29B$266.28M7 Day Performance0.93%0.63%0.18%-0.32%1 Month Performance10.58%6.31%6.26%3.44%1 Year Performance41.84%11.63%51.54%23.11% Protagonist Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTGXProtagonist Therapeutics1.7452 of 5 stars$59.60+2.6%$67.20+12.8%+42.6%$3.62B$434.43M85.14120News CoveragePositive NewsHigh Trading VolumeVTRSViatris1.782 of 5 stars$10.55-0.9%$10.40-1.4%-12.3%$12.42B$14.74B-3.6432,000RDYDr. Reddy's Laboratories2.788 of 5 stars$14.46-0.4%$16.95+17.3%-13.4%$12.11B$3.81B21.9027,811Positive NewsASNDAscendis Pharma A/S3.4483 of 5 stars$190.37-2.0%$243.36+27.8%+65.8%$11.89B$393.54M-36.891,017News CoveragePositive NewsAnalyst ForecastQGENQIAGEN4.276 of 5 stars$48.92-1.6%$49.69+1.6%+9.5%$11.06B$1.98B28.905,765Positive NewsMRNAModerna4.5595 of 5 stars$25.35-6.5%$42.88+69.2%-66.5%$10.55B$3.06B-3.375,800BBIOBridgeBio Pharma4.1797 of 5 stars$47.29-3.6%$61.35+29.7%+69.0%$9.38B$235.81M-11.56400Positive NewsAnalyst ForecastELANElanco Animal Health3.0977 of 5 stars$17.80-0.6%$17.33-2.6%+16.3%$8.90B$4.48B20.709,000Analyst RevisionVRNAVerona Pharma PLC American Depositary Share2.6177 of 5 stars$105.62+0.1%$109.00+3.2%+286.0%$8.64B$221.67M-106.6930News CoveragePositive NewsROIVRoivant Sciences3.1307 of 5 stars$11.64-2.3%$16.50+41.8%+7.0%$8.14B$29.05M-16.63860News CoveragePositive NewsAnalyst ForecastGRFSGrifols3.9341 of 5 stars$9.82-3.3%$10.30+4.9%+6.5%$6.99B$7.81B8.3923,822Positive NewsGap Up Related Companies and Tools Related Companies Viatris Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives QIAGEN Alternatives Moderna Alternatives BridgeBio Pharma Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Roivant Sciences Alternatives Grifols Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTGX) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTGX Stock Alerts